Home Tags Phase 3 ASCENT study

Tag: Phase 3 ASCENT study

Sacituzumab Govitecan Receives European Marketing Authorization for the Treatment of mTNBC...

The European Commission (EC) has granted marketing authorization for sacituzumab govitecan (Trodelvy®; Gilead Sciences) a first-in-class topoisomerase inhibitor antibody-drug conjugate (ADC) directed to the...

X